Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin followed by posaconazole for prevention of invasive fungal infection after high-risk liver transplantation
ChiCTR2100047646Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2021
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in invasive mycoses comparing Caspofungin prophylaxis with Caspofungin followed by posaconazole prophylaxis (2 arms). Primary endpoints: Incidence of fungal infection and Infection markers. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
caspofunginposaconazole
03
Conditions
invasive mycoses
Beyond the preview
Go deeper on ChiCTR2100047646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047646.